15 NOV 2018 BIOTECH DISPATCH
Anatara Lifesciences (ASX:ANR) has announced the appointment of Steven Lydeamore as its CEO.
The company is developing non-antibiotic oral solutions for gastrointestinal diseases in animals and humans.
Anatara’s Chair, Sue MacLeman, said the appointment is a key step in its development and transition to its focus on human health.
“We are very fortunate to have attracted someone of Steven’s calibre to lead Anatara at this important stage of the Company’s journey,” said Ms MacLeman. “Steve has demonstrated through his previous roles that he has the ability to successfully commercialise products on a global scale, driving growth and shareholder value.
The full article can be read here.